Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,031
  • Shares Outstanding, K 4,584
  • Annual Sales, $ 480 K
  • Annual Income, $ -11,570 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.25
  • Price/Sales 17.68
  • Price/Cash Flow N/A
  • Price/Book 3.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.87
  • Number of Estimates 1
  • High Estimate -0.87
  • Low Estimate -0.87
  • Prior Year -1.35
  • Growth Rate Est. (year over year) +35.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6250 +21.23%
on 12/19/24
2.4400 -19.26%
on 12/04/24
-0.0200 (-1.01%)
since 11/20/24
3-Month
1.6250 +21.23%
on 12/19/24
3.1716 -37.89%
on 09/30/24
-0.5700 (-22.44%)
since 09/20/24
52-Week
1.6250 +21.23%
on 12/19/24
10.7895 -81.74%
on 01/03/24
-7.7650 (-79.76%)
since 12/20/23

Most Recent Stories

More News
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BCDA : 1.9700 (+7.07%)
BioCardia, Inc. Completes Consultation with Japan's PMDA on BCDA-01 for Ischemic Heart Failure Treatment

BioCardia announces consultation success with PMDA for BCDA-01 registration, targeting ischemic heart failure treatment. Data expected Q1 2025.Quiver AI SummaryBioCardia, Inc., a leader in cell-derived...

BCDA : 1.9700 (+7.07%)
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BCDA : 1.9700 (+7.07%)
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BCDA : 1.9700 (+7.07%)
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BCDA : 1.9700 (+7.07%)
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BCDA : 1.9700 (+7.07%)
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval...

BCDA : 1.9700 (+7.07%)
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 1.9700 (+7.07%)
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 1.9700 (+7.07%)
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 1.9700 (+7.07%)

Business Summary

BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California....

See More

Key Turning Points

3rd Resistance Point 2.2457
2nd Resistance Point 2.1545
1st Resistance Point 2.0623
Last Price 1.9700
1st Support Level 1.8789
2nd Support Level 1.7877
3rd Support Level 1.6955

See More

52-Week High 10.7895
Fibonacci 61.8% 7.2887
Fibonacci 50% 6.2072
Fibonacci 38.2% 5.1258
Last Price 1.9700
52-Week Low 1.6250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar